Diabetes: Abbott takes FreeStyle glucose monitor off the U.S. market
August 31, 2011 by MassDevice staff
Abbott permanently discontinues its FreeStyle Navigator glucose monitoring system for U.S. consumers due to repeated supply disruptions.
Abbott Laboratories (NYSE:ABT) announced that it permanently discontinued its FreeStyle Navigator glucose monitor due to an inconsistent supply chain that has amounted to several disruptions in product availability for U.S. patients.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
- Heart Rhythm Society 2013 Scientific Session wrap-up
Navigation
NEWS
Can the FDA keep its user fee promises amid sequester?
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
Weight loss: EnteroMedics plans on Q1 PMA submission for Maestro device
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical's Q1 profits soar 1000%
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
Supreme Court to hear Medtronic's appeal of Boston Scientific's CRM patent win
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
Bayonne Medical Center tops 10 most expensive hospitals in America | MassDevice.com On-Call
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data
